AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22613015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (written information about inhalation techniques plus training by an instructor)
Number of subjects: 495
Study 22613015 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified in detail)
Number of subjects: 495
Study 20230348 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment of a project nurse to encourage best-practice falls injury prevention strategies during a 17-month intervention period.
Number of subjects: 5391
Study 20230348 — intervention group
Group type: COMPARATOR
Intervention: Control facilities (not specified intervention).
Number of subjects: 5391
Study 18986788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 12
Study 16439851 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1 or 2 mg/m2/day)
Number of subjects: 79
Study 16439851 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 79
Study 12705644 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-balanced ultrafiltration (ZBUF)
Number of subjects: 60
Study 12705644 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 11593632 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of tPA (Group I; n = 26)
Number of subjects: 80
Study 11593632 — intervention group
Group type: COMPARATOR
Intervention: 1.0-1.5 million U of urokinase (Group II; n = 54)
Number of subjects: 80
Study 8876751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral strength training (BIL)
Number of subjects: 48
Study 8876751 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral strength training (UNIL)
Number of subjects: 48
Study 1376503 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional histology (CH)
Number of subjects: 50
Study 1376503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine‐needle aspiration cytology (FNAC)
Number of subjects: 50
Study 1376503 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody staining of needle core biopsies (MABS)
Number of subjects: 50
Study 1376503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 4037535 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoggy Los Angeles ambient air exposure
Number of subjects: 59
Study 4037535 — intervention group
Group type: COMPARATOR
Intervention: Purified air exposure (control)
Number of subjects: 59
Study 30861351 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training exercise program (CTE) for 16 weeks, 3 times a week
Number of subjects: 49
Study 30861351 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 29210808 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg twice daily for 7 days)
Number of subjects: 29
Study 29210808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 7 days)
Number of subjects: 29
Study 26684684 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulip GT airway
Number of subjects: 60
Study 26684684 — intervention group
Group type: COMPARATOR
Intervention: Facemask with Guedel airway
Number of subjects: 60
Study 24708591 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dairy intake by 3.0 (± 1.2) serves/day for 1 month
Number of subjects: 180
Study 24708591 — intervention group
Group type: COMPARATOR
Intervention: Decreased dairy intake by 2.5 (± 1.2) serves/day
Number of subjects: 180
Study 24708591 — intervention group
Group type: COMPARATOR
Intervention: No change in dairy intake
Number of subjects: 180
Study 22126416 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-sens to peanut
Number of subjects: 38
Study 22126416 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-antibody to Ara h 1, 2, and 3
Number of subjects: 38
Study 19522751 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg/day for 9 days after bout 1)
Number of subjects: 33
Study 19522751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18630774 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine benzoate, 20 mg/kg IV
Number of subjects: 72
Study 18630774 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 72
Study 15685028 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 930
Study 15685028 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 930
Study 15685028 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (multiple myeloma subgroup)
Number of subjects: 930
Study 15685028 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (multiple myeloma subgroup)
Number of subjects: 930
Study 15685028 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (breast cancer subgroup)
Number of subjects: 930
Study 15685028 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (breast cancer subgroup)
Number of subjects: 930
Study 12122787 — intervention group
Group type: COMPARATOR
Intervention: X‐ray stimulation radiotherapy (6 x 0.5 Gy, 1 fraction/day)
Number of subjects: 30
Study 12122787 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT, 2000 pulses, energy flux density ED+ 0.1 mJ/mm2, 3 times in 1 week intervals)
Number of subjects: 30
Study 10607226 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (IFN) treatment
Number of subjects: 0
Study 10607226 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha2b treatment
Number of subjects: 0
Study 7781857 — intervention group
Group type: EXPERIMENTAL
Intervention: gemeprost
Number of subjects: 67
Study 7781857 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67
Study 2114064 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet comprising 55% fats
Number of subjects: 10
Study 2114064 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 10
Study 913045 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of adrenaline
Number of subjects: 0
Study 31865758 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 1312
Study 31865758 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) basal insulins
Number of subjects: 1312
Study 31018017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 96
Study 31018017 — intervention group
Group type: COMPARATOR
Intervention: Person‐Centred Experiential Therapy (PCET)
Number of subjects: 96
Study 28687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 20 mg every 4 hours
Number of subjects: 181
Study 28687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl 25 and 100 μg
Number of subjects: 181
Study 28687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hydromorphone 5 mg
Number of subjects: 181
Study 28687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine-6-glucuronide
Number of subjects: 181
Study 28687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Other nebulized opioids (various doses)
Number of subjects: 181
Study 28687551 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 181
Study 25047796 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexketoprofen trometamol (50 mg) and intraarticular normal saline (20 mL)
Number of subjects: 60
Study 25047796 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular 0.5 % levobupivacaine (100 mg) and intravenous normal saline (2 mL)
Number of subjects: 60
Study 25047796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular 0.5 % levobupivacaine (100 mg) and intravenous dexketoprofen trometamol (50 mg)
Number of subjects: 60
Study 22717938 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention for caregivers
Number of subjects: 140
Study 19346278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 60
Study 19346278 — intervention group
Group type: COMPARATOR
Intervention: Control (non-medicated group)
Number of subjects: 60
Study 18157648 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery plus whole brain irradiation (WBRT)
Number of subjects: 64
Study 18157648 — intervention group
Group type: COMPARATOR
Intervention: Gamma Knife surgery alone
Number of subjects: 64
Study 15684155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin bolus (10 IU push)
Number of subjects: 201
Study 15684155 — intervention group
Group type: COMPARATOR
Intervention: Dilute oxytocin infusion (10 IU in 500 mL saline at 125 mL/h)
Number of subjects: 201
Study 12851521 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous‐combined hormone replacement therapy (0.625 mg/day conjugated equine estrogen plus 5 mg/day medroxyprogesterone)
Number of subjects: 40
Study 12851521 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT treatment)
Number of subjects: 40
Study 10066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial body temperature of 36 degrees C
Number of subjects: 7
Study 10066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial body temperature of 37 degrees C
Number of subjects: 7
Study 10066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial body temperature of 38 degrees C
Number of subjects: 7
Study 10066720 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate of heat storage (0.10 degrees C/min)
Number of subjects: 7
Study 10066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low rate of heat storage (0.05 degrees C/min)
Number of subjects: 7
Study 10066720 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate of heat storage
Number of subjects: 7
Study 10066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low rate of heat storage
Number of subjects: 7
Study 8739809 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 16
Study 8739809 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 16
Study 1912052 — intervention group
Group type: EXPERIMENTAL
Intervention: 1988 survey
Number of subjects: 1352
Study 1912052 — intervention group
Group type: EXPERIMENTAL
Intervention: 1989 survey
Number of subjects: 1352
Study 1912052 — intervention group
Group type: COMPARATOR
Intervention: 1988 and 1989 surveys
Number of subjects: 1352
Study 6758933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (intravenous and/or oral)
Number of subjects: 22
Study 29228473 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50, 100, and 200 mg)
Number of subjects: 30
Study 27043082 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod (7.5 mg, twice daily)
Number of subjects: 3503
Study 27043082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3503
Study 27043082 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 3503
Study 24910199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (80% of VO2max) for 40 min
Number of subjects: 6
Study 24910199 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise (40% of VO2max) for 20 min
Number of subjects: 6
Study 22810991 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape polyphenol powder (GRAPE)
Number of subjects: 24
Study 22810991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20557835 — intervention group
Group type: EXPERIMENTAL
Intervention: S-etodolac ER 300 mg
Number of subjects: 108
Study 20557835 — intervention group
Group type: COMPARATOR
Intervention: etodolac ER 600 mg
Number of subjects: 108
Study 18401713 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 194
Study 18401713 — intervention group
Group type: COMPARATOR
Intervention: Stepwise vocational program
Number of subjects: 194
Study 16391215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention with group and individual sessions promoting decreased fat intake and increased vegetable, fruit, and grain consumption.
Number of subjects: 48835
Study 16391215 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving diet-related education materials.
Number of subjects: 48835
Study 12817528 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide alone
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with ketoconazole
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with ethinyloestradiol/levonorgestrel
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with simvastatin
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with nifedipine
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with ketoconazole and rifampicin
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with simvastatin or nifedipine
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with CYP3A4 substrates (ethinyloestradiol/levonorgestrel, simvastatin, nifedipine)
Number of subjects: 0
Study 12817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with strong inhibitors or inducers of CYP3A4
Number of subjects: 0
Study 11293210 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination
Number of subjects: 76
Study 11293210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 76
Study 8880180 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion product otoacoustic emission (DPOAE) iso-suppression tuning curves (STC)
Number of subjects: 31
Study 8880180 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE STC
Number of subjects: 31
Study 8880180 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoacoustic tuning curves (PTC)
Number of subjects: 31
Study 8880180 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal STCs
Number of subjects: 31
Study 8880180 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE suppression
Number of subjects: 31
Study 8880180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear tuning
Number of subjects: 31
Study 2057103 — intervention group
Group type: EXPERIMENTAL
Intervention: phytostimolin cream and vaginal lavage
Number of subjects: 60
Study 6337761 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol (30- or 60-mg tablets, twice daily for 14 days)
Number of subjects: 14
Study 6337761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 days prior to indenolol)
Number of subjects: 14
Study 31257605 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy and environmental change intervention
Number of subjects: 636
Study 31257605 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 636
Study 30557350 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning with simulation-based training for postpartum hemorrhage and neonatal asphyxia management
Number of subjects: 199
Study 30557350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study 30557350 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 199
Study 26628249 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy‐Health Care (MST‐HC)
Number of subjects: 170
Study 26628249 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 170
Study 23992543 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM subjects (n=25)
Number of subjects: 25
Study 23992543 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls (n=16)
Number of subjects: 25
Study 22270216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (steroid group) for 15 days starting with 100 mg at surgery, tapered to 12.5 mg.
Number of subjects: 220
Study 22270216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) administered in a comparable manner to the steroid group.
Number of subjects: 220
Study 22270216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (steroid group)
Number of subjects: 220
Study 22270216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 220
Study 22270216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study 20669035 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help workbook intervention
Number of subjects: 40
Study 20669035 — intervention group
Group type: COMPARATOR
Intervention: No-workbook control
Number of subjects: 40
Study 17207145 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the trial (all children)
Number of subjects: 461
Study 17207145 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the trial (some children)
Number of subjects: 461
Study 17207145 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the trial (none)
Number of subjects: 461
Study 17207145 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with all children participating
Number of subjects: 461
Study 17207145 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with some children participating
Number of subjects: 461
Study 17207145 — intervention group
Group type: EXPERIMENTAL
Intervention: Future use of the Vi vaccine
Number of subjects: 461
Study 16444992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymphoscintigrams in patients undergoing excisional biopsy
Number of subjects: 159
Study 16444992 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymphoscintigrams in patients without excisional biopsy
Number of subjects: 159
Study 12873566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (osmolality 1030 mOsm/kg)
Number of subjects: 0
Study 12873566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid (pH 1 and 2.5)
Number of subjects: 0
Study 12873566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified hypertonic saline (pH 1 and 2.5)
Number of subjects: 0
Study 12873566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 0
Study 12873566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid
Number of subjects: 0
Study 12873566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified hypertonic saline
Number of subjects: 0
Study 10554747 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine plus lidocaine cream (Group A)
Number of subjects: 180
Study 10554747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (Group B)
Number of subjects: 180
Study 10554747 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (Control Group C)
Number of subjects: 180
Study 8725992 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates from hospitalized diabetic patients
Number of subjects: 300
Study 8725992 — intervention group
Group type: COMPARATOR
Intervention: E. coli isolates from non-hospitalized diabetic patients
Number of subjects: 300
Study 8725992 — intervention group
Group type: COMPARATOR
Intervention: E. coli isolates from non-diabetic patients
Number of subjects: 300
Study 1659601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot assay using recombinant-baculovirus-expressed glycoprotein G (gG1 or gG2)
Number of subjects: 110
Study 1659601 — intervention group
Group type: COMPARATOR
Intervention: Immunodot assay based on gG immunopurified from HSV-1 and HSV-2 infected cells
Number of subjects: 110
Study 1659601 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of the immunoblot assay
Number of subjects: 110
Study 1659601 — intervention group
Group type: EXPERIMENTAL
Intervention: Results from two laboratories
Number of subjects: 110
Study 7032852 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol (TAA)
Number of subjects: 96
Study 7032852 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 96
Study 30679183 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic ASC sheets
Number of subjects: 59
Study 30679183 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane film
Number of subjects: 59
Study 30121091 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation with locked plating technology
Number of subjects: 160
Study 30121091 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management
Number of subjects: 160
Study 27884853 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyejibongneyong-hwan (GBH) administered three times per day for two menstrual periods (8 weeks)
Number of subjects: 38
Study 27884853 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times per day for two menstrual periods (8 weeks)
Number of subjects: 38
Study 25086653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (8g) for 11 days
Number of subjects: 67
Study 22172638 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic psychosocial stressors
Number of subjects: 48
Study 19466245 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reformations using shaded surface display (SSD)
Number of subjects: 22
Study 19466245 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reformations using maximum intensity projection (MIP)
Number of subjects: 22
Study 19466245 — intervention group
Group type: COMPARATOR
Intervention: Multiplanar reformation (MPR)
Number of subjects: 22
Study 17882046 — intervention group
Group type: EXPERIMENTAL
Intervention: 80, 100, and 120 kVp with 100, 150, and 200 mA (experiment 1)
Number of subjects: 13
Study 17882046 — intervention group
Group type: EXPERIMENTAL
Intervention: 140, 180, and 220 mA with 100 and 120 kVp (experiment 2)
Number of subjects: 13
Study 17882046 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly used mAs between 60 and 220 with 100 and 120 kVp (experiment 3)
Number of subjects: 13
Study 15908760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream preparations containing marigold and rosemary extracts
Number of subjects: 0
Study 15908760 — intervention group
Group type: COMPARATOR
Intervention: Control group with undyed marigold and faradiol ester-enriched extracts
Number of subjects: 0
Study 15908760 — intervention group
Group type: COMPARATOR
Intervention: Control group with dyed and undyed rosemary extracts
Number of subjects: 0